Semaglutide vs Tirzepatide for Obesity: What the Data Show

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery

Key Takeaways From Recent Trials

• Tirzepatide produced substantially greater average weight loss than semaglutide at 72 weeks in the SURMOUNT-5 head-to-head trial.¹
• Both medications cause lean-mass loss in proportion to total weight lost; resistance training and higher protein intake help preserve muscle.¹
• GI-related discontinuation occurred less often with tirzepatide than with semaglutide, although individual tolerability varies.
• Most patients regain a meaningful share of lost weight after stopping either medication, so structured maintenance plans matter for long-term success.¹
• Patients who want lab-guided GLP-1 or GLP-3R protocols with a focus on muscle preservation can book an appointment with Ellie at Mirror Plastic Surgery.

Weight-Loss Magnitude in SURMOUNT-5

SURMOUNT-5 enrolled 751 adults with obesity and no type 2 diabetes and tracked percentage change in body weight at week 72 as the primary endpoint. Tirzepatide produced meaningfully greater average weight loss than semaglutide over this period.¹ Key responder rates from SURMOUNT-5 highlight this gap, with a higher share of tirzepatide patients reaching larger total body-weight reductions compared with semaglutide.

Waist circumference also improved more with tirzepatide, with an average reduction of 18.4 cm versus 13.0 cm for semaglutide.¹ A 2026 network meta-analysis by Bernardi et al. in the Journal of Diabetes, which pooled 28 randomized controlled trials and 34,367 adults, ranked tirzepatide as the most effective agent for percentage weight loss compared with semaglutide 2.4 mg.

Body Composition, Muscle Retention, and GLP-1 Therapy

Lean-mass loss occurs consistently during GLP-1 therapy across multiple trials. The SURMOUNT-1 DXA substudy found that tirzepatide produced approximately 75% fat mass and 25% lean mass as a proportion of total weight lost, matching the placebo arm.¹ This pattern suggests a general weight-loss physiology effect rather than a drug-specific problem.

SURMOUNT-5 reported a similar percentage of lean mass lost for tirzepatide and semaglutide. Because tirzepatide drives greater total weight loss, patients on tirzepatide lose more absolute pounds of lean tissue even though the proportion is comparable.

An April 2026 preprint that followed more than 8,000 patients across 14 U.S. health systems quantified this difference. Tirzepatide users lost an average of 1.8 kg more lean mass than semaglutide users over 52–72 weeks, with the gap largest in adults over 60 and in those not performing regular resistance training.¹ A Vienna retrospective cohort of 486 adults on GLP-1RA therapy added nuance. When researchers adjusted for fat-mass changes, relative skeletal muscle mass remained stable or increased in more than 70% of patients, suggesting that some apparent lean-mass loss may reflect fluid shifts or measurement artifacts rather than true muscle depletion.¹

Several strategies help protect lean mass during GLP-1 therapy:

• Protein intake of 1.6–2.0 g/kg body weight per day, spread across 3–4 meals with 25–40 g protein each
• Progressive resistance training at least two times per week
• At least 150 minutes per week of moderate-to-vigorous aerobic activity
• Regular body-composition monitoring with DEXA or validated BIA to track lean-mass trends
• Lab-guided review of metabolic markers to flag patients at higher risk of lean-tissue depletion

Book an appointment with Ellie to review your lab work and design a protocol that prioritizes lean-mass preservation throughout your weight-loss plan.

Gastrointestinal Side Effects and Tolerability

In SURMOUNT-5, GI-related discontinuation occurred less often with tirzepatide than with semaglutide, and the trial reported rates of nausea, diarrhea, vomiting, and constipation for both drugs.¹ GI symptoms with either agent usually peak during the first 4–8 weeks of initiation or dose escalation and often ease once patients reach a stable maintenance dose.

Both medications follow structured titration schedules to reach maximum doses, which helps reduce GI burden. A 2026 meta-analysis of three head-to-head randomized trials found no significant difference in overall adverse events or GI events between tirzepatide and semaglutide, although individual experiences can differ.

Safety Considerations and Who Should Avoid These Medications

Semaglutide and tirzepatide both carry an FDA black-box warning for thyroid C-cell tumors based on rodent data and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). Several additional safety points guide clinical decision-making:

• Patients with severe gastroparesis should avoid both medications.
• Semaglutide includes a labeled precaution for diabetic retinopathy complications that does not appear in tirzepatide labeling.
• Pancreatitis remains a rare but serious risk with both agents, and severe abdominal pain radiating to the back requires urgent evaluation.
• A December 2025 TGA advisory reported that tirzepatide may reduce the effectiveness of oral contraceptives.
• Patients with active pancreatitis, severe renal impairment, or complex drug interactions need individualized review before starting either medication.

Maintaining Results After You Stop Treatment

Published extension data show that many patients regain a large share of lost weight within one year of stopping semaglutide or tirzepatide.¹ STEP-1 extension results showed that patients who reached about 17% mean body-weight loss on semaglutide retained only about 6% net loss by week 120.¹ SURMOUNT-4 showed that patients switched from tirzepatide to placebo at week 36 regained around 14% body weight by week 88.¹

Several habits and clinical strategies support weight maintenance after active treatment:

• Starting a structured exercise routine, including progressive resistance training, before treatment ends
• Reducing ultra-processed food intake to avoid an average increase of roughly 500 calories per day
• Transitioning to a supervised maintenance peptide protocol instead of stopping abruptly
• Continuing lab monitoring to detect early metabolic drift and adjust treatment plans

Side-by-Side Data Comparison for Quick Review

The following table brings together key efficacy, body-composition, GI tolerability, and titration data so you can compare semaglutide and tirzepatide at a glance.

Medication	Mean Weight Loss (%)	Lean-Mass Fraction of Weight Lost (%)	GI Discontinuation (%)	Titration Schedule
Tirzepatide (max tolerated dose)	20.2% at 72 weeks (SURMOUNT-5, NEJM 2025)	~25% (SURMOUNT-1 DXA substudy)	2.7% (SURMOUNT-5, NEJM 2025)	2.5 mg → 15 mg over 20 weeks
Semaglutide (max tolerated dose)	13.7% at 72 weeks (SURMOUNT-5, NEJM 2025)	~40% (STEP-1 body-composition data)	5.6% (SURMOUNT-5, NEJM 2025)	0.25 mg → 2.4 mg over 16 weeks

Note: Lean-mass fraction figures come from separate body-composition substudies (SURMOUNT-1 DXA and STEP-1), not from SURMOUNT-5 itself. Cross-trial comparisons should be interpreted cautiously because of differences in measurement methods and patient populations.

Decision Guide for Florida Patients

Choosing between semaglutide, tirzepatide, or a supervised alternative works best when you match the drug profile to your specific goals and medical history. Several factors often guide that choice:

• Weight-loss magnitude goal: Patients who want the largest possible weight reduction and do not have established cardiovascular disease often favor tirzepatide, which has strong evidence from SURMOUNT-1 and SURMOUNT-5.
• Cardiovascular history: Semaglutide has demonstrated a 20% relative risk reduction in major adverse cardiovascular events in patients with established cardiovascular disease in the SELECT trial.
• GI tolerability history: Patients who stopped semaglutide because of nausea sometimes tolerate tirzepatide’s titration curve better, and the reverse can also occur.
• Muscle-preservation priority: Adults over 60, those with low baseline muscle mass, or those unable to perform regular resistance training benefit from closer body-composition monitoring on either agent.
• Insurance and access: Real-world 12-month adherence (PDC ≥0.80) remains low, at 15.9% for semaglutide and 13.9% for tirzepatide among commercially insured U.S. adults treated for obesity, which makes structured support important.
• Supervised alternatives: Some patients qualify for newer-generation peptide protocols that aim for similar efficacy with different tolerability profiles under medical oversight.

GLP-3R at Mirror Plastic Surgery: A Newer-Generation Option

GLP-3R is a newer-generation compounded peptide that acts on mechanisms related to GLP-1 pathways. At Mirror Plastic Surgery, GLP-3R is available only within a concierge protocol that includes detailed lab review of thyroid, liver, kidney, diabetes markers, and hormone panels before treatment begins. Reported GLP-3R characteristics include a lower GI burden than older GLP-1 agents and reduced muscle-wasting potential, which may help patients who experienced severe GI side effects or notable lean-mass loss on semaglutide or tirzepatide.

Because GLP-3R is a compounded peptide and not FDA-approved for these indications, individualized clinical evaluation remains essential. Ellie Pranckevicius reviews each patient’s metabolic profile, medication list, and body-composition data to decide whether GLP-3R fits and how to stack it with complementary peptides such as Sermorelin/Ipamorelin to support muscle retention.

Book an appointment with Ellie to see whether GLP-3R or another supervised peptide protocol aligns with your metabolic profile and weight-loss goals.

Meet Your Practitioner: Ellie Pranckevicius, FNP-BC

Ellie Pranckevicius is a board-certified Family Nurse Practitioner and the lead peptide-therapy practitioner at Mirror Plastic Surgery. She holds a Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and earned both her Bachelor’s and Master’s in Nursing from the University of South Florida. Four years in the Neuroscience ICU at Tampa General Hospital gave her deep experience with physiology, metabolic health, and complex patient management, which she now applies to weight-management and body-composition protocols.

Ellie’s combined background in esthetic care and advanced nursing helps her connect desired aesthetic outcomes with the clinical science needed to reach them safely. She focuses on education, explains the physiology behind each recommendation in clear language, tells patients when a service is not yet appropriate, and provides 24/7 concierge support throughout treatment.

Summary and Next Steps for Your Weight-Loss Plan

SURMOUNT-5, published in the New England Journal of Medicine in May 2025, confirmed a meaningful efficacy gap between tirzepatide and semaglutide at 72 weeks. Tirzepatide shows lower GI discontinuation in head-to-head data, while semaglutide currently holds the key cardiovascular outcomes evidence in high-risk patients. Both medications cause lean-mass loss in proportion to total weight lost and both generally require continued treatment to maintain results.

Florida adults who have plateaued on standard GLP-1 therapy, struggled with side effects, or worry about muscle preservation benefit from a lab-guided evaluation with a clinically trained practitioner before starting or switching any protocol. Schedule your consultation to receive a personalized, lab-informed assessment of your weight-management options, including GLP-3R and complementary peptide stacks.

Frequently Asked Questions

Do you lose more muscle on semaglutide or tirzepatide?

The Body-Composition Outcomes section above explains that both drugs produce a similar proportion of lean-mass loss relative to total weight lost. Tirzepatide’s greater overall weight loss means more absolute pounds of lean tissue are lost on average, especially at higher weight-loss thresholds and in older adults or those not lifting weights. The same mitigation strategies discussed earlier, including resistance training, higher protein intake, and body-composition monitoring, remain crucial regardless of which agent you use.

Do people tolerate tirzepatide better than semaglutide?

Head-to-head SURMOUNT-5 data showed lower GI-related discontinuation with tirzepatide and lower rates of nausea, vomiting, diarrhea, and constipation in that trial. A 2026 meta-analysis of three randomized head-to-head studies, however, did not find a statistically significant difference in overall adverse events or GI events between the two drugs and reported a higher rate of serious adverse events with tirzepatide. Individual responses vary, and some patients tolerate one agent far better than the other.

Both medications require slow dose titration, typically over 16 weeks for semaglutide and 20 weeks for tirzepatide, to reduce GI burden. Patients who continue to struggle with GI side effects on either drug may qualify for GLP-3R within Ellie’s supervised protocol at Mirror Plastic Surgery.

What happens to weight after stopping semaglutide or tirzepatide?

Extension trials such as STEP-1, STEP-4, and SURMOUNT-4 show that patients often regain roughly two-thirds of the weight they lost within a year of fully stopping these medications.¹ Earlier sections describe how gastric emptying speeds up, hunger hormones rebound, and cardiometabolic benefits drift back toward baseline once treatment ends. Strategies that reduce regain include starting resistance training before discontinuation, keeping protein intake high, limiting ultra-processed foods, and shifting to a lower-dose maintenance protocol instead of stopping suddenly.

At Mirror Plastic Surgery, Ellie works with patients to build long-term maintenance plans that may include maintenance peptide dosing and ongoing lab monitoring to preserve as much of the weight-loss benefit as possible.

What is GLP-3R and how does it differ from semaglutide or tirzepatide?

GLP-3R is a compounded peptide that acts on mechanisms related to GLP-1 pathways but is not an FDA-approved pharmaceutical. Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GLP-1 and GIP receptor agonist, while GLP-3R is available only through compounded, medically supervised protocols. Reported advantages of GLP-3R include fewer GI side effects than older GLP-1 agents and a lower likelihood of muscle wasting, along with potential applications in insulin resistance and cardiovascular risk-factor management.

Because GLP-3R is not FDA-regulated, it should never be used without medical supervision. At Mirror Plastic Surgery, GLP-3R is considered only after a comprehensive consultation that includes full lab panels, medical history review, and assessment of prior treatment responses. Ellie sources peptides from reputable compounding pharmacies that perform rigorous batch testing for purity and accurate dosing.

Is a supervised peptide protocol at Mirror Plastic Surgery right for me if I live in Tampa or St. Petersburg?

Mirror Plastic Surgery offers peptide protocols to patients in the St. Petersburg and Tampa Bay area and to eligible patients across the United States via telemedicine. The process starts with a 30–60 minute consultation with Ellie Pranckevicius, who reviews your medical history, current medications, and health goals. For weight management, she orders or reviews a full lab panel that includes thyroid, liver, kidney, diabetes markers, and hormone levels before recommending any protocol.

Based on those results, Ellie designs a personalized peptide stack that may include GLP-3R, Sermorelin/Ipamorelin for muscle retention, or other targeted peptides. Ongoing support includes direct text access, telemedicine visits, and detailed self-administration guidance. This level of individualized, concierge oversight distinguishes Mirror Plastic Surgery from unsupervised online peptide sources and high-volume telemedicine platforms.

Medical, Regulatory, and Outcomes Disclaimers

This article provides general educational information and does not replace medical advice, diagnosis, or treatment. Individual results from semaglutide, tirzepatide, GLP-3R, or any other peptide therapy vary based on genetics, baseline health, adherence, lifestyle, and other factors. GLP-3R and other peptides mentioned here are not FDA-approved for obesity or any other indication discussed in this article. Compounded peptides do not undergo FDA review for safety, efficacy, or manufacturing quality in the same way as approved pharmaceuticals.

All treatment decisions should be made with a qualified, licensed healthcare provider who has reviewed your full medical history and current lab data. Mirror Plastic Surgery’s peptide protocols are supervised by Ellie Pranckevicius, FNP-BC, and tailored to each patient’s clinical profile. Nothing in this article guarantees specific outcomes.

---